Reconsideration of sample size and power calculation for overall survival in cancer clinical trials

Chakravarty, 2008, Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues, Stat. Methods Med. Res., 17, 515, 10.1177/0962280207081862 Giessen, 2013, Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials, Clin. Canc. Res., 19, 225, 10.1158/1078-0432.CCR-12-1515 Booth, 2012, Progression-free survival: meaningful or simply measurable?, J. Clin. Oncol., 30, 1030, 10.1200/JCO.2011.38.7571 Broglio, 2009, Detecting an overall survival benefit that is derived from progression-free survival, J. Natl. Cancer Inst. (Bethesda), 101, 1642, 10.1093/jnci/djp369 Morita, 2009, Detecting overall survival benefit derived from survival postprogression rather than progression-free survival, J. Natl. Cancer Inst. (Bethesda), 101, 1642, 10.1093/jnci/djp369 Cortes, 2011, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 377, 914, 10.1016/S0140-6736(11)60070-6 Heinemann, 2014, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol., 15, 1065, 10.1016/S1470-2045(14)70330-4 Schoenfeld, 1981, The asymptotic properties of nonparametric tests for comparing survival distributions, Biometrika, 68, 316, 10.1093/biomet/68.1.316 Jones, 2009 Sundar, 2012, A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer, Gynecol. Oncol., 125, 493, 10.1016/j.ygyno.2011.12.420